RE: Potential Investor20 Feb 2022 09:43
Interesting to see if there are any holding notifications next week. Over 40% of shares are held by institutions, and somewhere in the region of 25% by private firms. Retail investors account for just over 13%..just reread the hardman report with the 281p target, well worth a read. I think you can download straight from Herdman and co. As far as I can see they have equalled or exceeded their initial 2021 USA remit to increase market awareness and payer coverage. They've done that with bells. Hardman forecasted just under £8 million cash at hand. (Results £12 million) so they are well within spend guidelines. Suggests good financial management which is good to see.
Revenue. Forecast at £3.6 million (actual £1.5). This is the primary origin for the bear case which appears to be solely based on accountancy facts. Nothing wrong with that. In fact in 90 % of cases minimum, it's perfect. However, the Shield strategy of building up market awareness and payer coverage is dismissed entirely by looking at the results as there will be a skew to the downside looking at current results. The coverage is now there and no mean feat I imagine. Shield provided no targets for USA Revenue in 2021 as they new the first 6 months stateside would be all about setting payer coverage up for 2022. Now it's in place, we can assume that they will adjust their pricing accordingly and crank up Revenue quickly.
This is a bear raid, exploiting the disconnect in results and payer coverage at nominal pricing. Watch for large institutional holding adjustments for 'inforned clues'. Are they selling or not
Shorters are borrowing stock on loan. When they close, they buy and the SP rebounds, sometimes violently. Time to buy soon.
GLA. DYOR and read the report and do your own analysis. At worst Shield are a couple of months behind schedule in the states imo. Pricing adjustments imminent with a simultaneous ramp up in prescriptions and Revenue will follow. Off the back of that debt facility, will be a pieceof****. Shield is debt free no loans, no bond holders, with a small market cap. Sales costs are also front loaded and it will sell itself, one embedded in the system.
A lot more to like than not to like at the current SP.
GLA. I won't be engaging in BB spates next week. I know the bear case like we do/should and don't feel I need to defend my views to anyone :)